GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Neuren Pharmaceuticals Ltd (ASX:NEU) » Definitions » Book Value per Share

Neuren Pharmaceuticals (ASX:NEU) Book Value per Share : A$2.54 (As of Jun. 2024)


View and export this data going back to 2005. Start your Free Trial

What is Neuren Pharmaceuticals Book Value per Share?

Neuren Pharmaceuticals's book value per share for the quarter that ended in Jun. 2024 was A$2.54.

During the past 12 months, Neuren Pharmaceuticals's average Book Value Per Share Growth Rate was 262.60% per year. During the past 3 years, the average Book Value Per Share Growth Rate was 97.20% per year. During the past 5 years, the average Book Value Per Share Growth Rate was 43.20% per year. During the past 10 years, the average Book Value Per Share Growth Rate was 13.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Neuren Pharmaceuticals was 97.20% per year. The lowest was -65.00% per year. And the median was 9.30% per year.

Neuren Pharmaceuticals's current price is A$12.35. Its book value per share for the quarter that ended in Jun. 2024 was A$2.54. Hence, today's PB Ratio of Neuren Pharmaceuticals is 7.67.

During the past 13 years, the highest P/B Ratio of Neuren Pharmaceuticals was 76.83. The lowest was 4.11. And the median was 10.59.


Neuren Pharmaceuticals Book Value per Share Historical Data

The historical data trend for Neuren Pharmaceuticals's Book Value per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neuren Pharmaceuticals Book Value per Share Chart

Neuren Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Book Value per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.14 0.21 0.31 0.33 1.61

Neuren Pharmaceuticals Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Book Value per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.25 0.33 0.70 1.61 2.54

Competitive Comparison of Neuren Pharmaceuticals's Book Value per Share

For the Biotechnology subindustry, Neuren Pharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Neuren Pharmaceuticals's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Neuren Pharmaceuticals's PB Ratio distribution charts can be found below:

* The bar in red indicates where Neuren Pharmaceuticals's PB Ratio falls into.



Neuren Pharmaceuticals Book Value per Share Calculation

Neuren Pharmaceuticals's Book Value Per Share for the fiscal year that ended in Dec. 2023 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(208.9-0.0)/129.7
=1.61

Neuren Pharmaceuticals's Book Value Per Share for the quarter that ended in Jun. 2024 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(330.0-0.0)/130.1
=2.54

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.

Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.


Neuren Pharmaceuticals  (ASX:NEU) Book Value per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.


Neuren Pharmaceuticals Book Value per Share Related Terms

Thank you for viewing the detailed overview of Neuren Pharmaceuticals's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Neuren Pharmaceuticals Business Description

Traded in Other Exchanges
Address
697 Burke Road, Suite 201, Camberwell, Melbourne, VIC, AUS, 3124
Neuren Pharmaceuticals Ltd is a biopharmaceutical company, which engages in the development of new therapies for brain injury, neurodevelopment disorders. Its drugs target symptoms resulting from acute traumatic brain injury, as well as symptoms of chronic conditions, such as Rett syndrome and Fragile X syndrome. The Group has two reportable operating segments, Commercial Products and Research and Development. It derives maximum revenue from Commercial Products.